



ASX Announcement

11 August 2014

## **Agenix receives proceeds of more than \$AUD2 Million from its AGX-1009 China Asset sale to Cinkate Pharmaceuticals**

**Melbourne, Australia, 8 August 2014:** Agenix Limited (ASX: AGX) advises that its wholly owned subsidiary in China has received RMB 11,741,864 (\$AUD 2,056,729) being the proceeds due for the sale of its AGX-1009 China project to Cinkate Pharmaceutical Intermediates Co Ltd (**Cinkate**).

Under the terms of the sale announced on 19 May 2011, Cinkate has taken over development of AGX-1009, a tenofovir prodrug for HBV patented in China sold by Agenix following completion of preclinical studies.

Four three-party cooperation agreements were also signed by Cinkate, Agenix and its Chinese development partners: the Institute of Medicinal Biotechnology, the Institute of Pharmacology and Toxicology of the Academy of Military Medical Sciences, the Institute of Radiation Medicine of the Academy of Military Medical Sciences, and HongHui Meditech.

Agenix chairman and chief executive Nick Weston said "The proceeds from the sale of AGX-1009 demonstrates our focus on strengthening our balance sheet and exiting all operations in China."

For more information please contact:

Nicholas Weston

Tel: +61 3 8616 0379

## **About Agenix**

Agenix listed on the Australian Securities Exchange in 1987. Today, Agenix's lead product candidate is ThromboView®, a novel radio-labelled monoclonal antibody imaging modality for pulmonary embolism (PE) and deep vein thrombosis (DVT). ThromboView® has successfully completed two U. S. FDA Phase II clinical trials and is seeking a partner for Phase III trials.

Agenix's human health diagnostics platform, DiagnostIQ® is a patented disposable point-of-care test device with reader. DiagnostIQ® utilises an antibody/antigen printed membrane, a unique pre-filter device and an incubation chamber in a flow-through format to create a sensitive and quantitative, rapid, test. The patented technology is partnered with Arrayjet® of Scotland, one of the world's leading microarray printer manufacturers, for development as a point of care (PoC) microarray platform.